TY - JOUR
T1 - Targeted and tailored therapy in hemato-oncology
T2 - Vision for the 21st century
AU - Shpilberg, Ofer
AU - Ben-Bassat, Isaac
AU - Raanani, Pia
PY - 2006/12
Y1 - 2006/12
N2 - Summarizing our vision of hemato-oncology in the 21st century, we believe that with time, and with the expected progress in both medicine and biotechnology, the role of non-specific chemotherapy will decrease, while that of targeted therapies will increase. Unfortunately, for most tumors chemotherapy is still the cornerstone of treatment. We should therefore focus on finding more targeted agents, better tailoring of treatments, and identifying the risk factors for cancer development and the means of prevention of - what is likely to be - the number one killer of this century.
AB - Summarizing our vision of hemato-oncology in the 21st century, we believe that with time, and with the expected progress in both medicine and biotechnology, the role of non-specific chemotherapy will decrease, while that of targeted therapies will increase. Unfortunately, for most tumors chemotherapy is still the cornerstone of treatment. We should therefore focus on finding more targeted agents, better tailoring of treatments, and identifying the risk factors for cancer development and the means of prevention of - what is likely to be - the number one killer of this century.
KW - Hemato-oncology
KW - Tailored therapy
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=33845900673&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 17214100
AN - SCOPUS:33845900673
SN - 1565-1088
VL - 8
SP - 843
EP - 844
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 12
ER -